NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)
$0.84
-0.0799 ( -8.65% ) 497.7K
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Market Data
Open
$0.84
Previous close
$0.92
Volume
497.7K
Market cap
$15.85M
Day range
$0.80 - $0.95
52 week range
$0.40 - $2.33
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 35 | Jan 09, 2024 |
6-k | Quarterly Reports | 3 | Dec 27, 2023 |
6-k | Quarterly Reports | 35 | Dec 21, 2023 |
6-k | Quarterly Reports | 3 | Dec 14, 2023 |
6-k | Quarterly Reports | 5 | Dec 05, 2023 |
6-k | Quarterly Reports | 3 | Nov 28, 2023 |
6-k | Quarterly Reports | 3 | Nov 13, 2023 |
6-k | Quarterly Reports | 3 | Nov 06, 2023 |
6-k | Quarterly Reports | 4 | Oct 17, 2023 |
6-k | Quarterly Reports | 5 | Oct 04, 2023 |